Date: July 30, 2020

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Limited,  
Exchange Plaza, C-1, Block-G, Bandra-Kurla Complex,  
Bandra (E), Mumbai-400 051.  
Scrip Code – LINCOLN

To,  
The Department of Corporate Service,  
BSE Limited,  
1st Floor, New Trading Ring,  
Rotunda Building, Phiroze Jeejeebhoy Tower,  
Dalal Street, Mumbai-400 001.  
Scrip Code – 531633

Dear Sir,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed a Press Release titled “Lincoln Pharmaceuticals Limited launches Vitamin C+ Zinc Tablets to boost immunity in the fight against CoVID-19”.

We request you to kindly take the above on record.

Thanking you,

Yours faithfully,

FOR LINCOLN PHARMACEUTICALS LIMITED

NIREN A. DESAI  
[COMPANY SECRETARY]

Encl: a/a
Media Release

Lincoln Pharmaceuticals Limited launches Vitamin C + Zinc Tablets to boost immunity in the fight against COVID 19

July 30, 2020: With a commitment towards "Healthcare For All", Lincoln Pharmaceuticals Limited, one of India's leading healthcare companies has launched Chewable Vitamin C + Zinc Tablet for the markets in India. The tablet is an evidence-based bio-active for natural immunity in combination of zinc that boosts antiviral activity and protection against COVID 19. Market size for Vitamin C and Zinc tablets is estimated at around Rs. 150 crore in India and growing at 15% per annum.

Mr. Ashish R. Patel, Whole-Time Director, Lincoln Pharmaceuticals Limited, said, "During this CoVID-19 Pandemic, Immunity & immunity boosters are the only way to protect against the Virus. Vitamin-C & Zinc tablet have become necessity and important part of all human being in their day to day life. With this launch, we aim to fill the gaps in serving the healthcare requirement of the masses with our wide range of 600 plus formulations. As it is in the form of Chewable Tablet, Geriatric and pediatric patients and travelling patients who may not have ready access to water are most need of easy swallowing dosage forms like chewable tablets with pleasant flavor. Company is committed to fight the COVID-19 pandemic and working closely with the governments and relevant stakeholders to ensure uninterrupted supply of medicines."

Lincoln Pharmaceuticals Limited is one of the leading companies in Pharmaceutical industry, engaged in the business of manufacturing of Tablets, Capsules, Dry Syrup, Liquid Vials, Injectables and Ointments etc. The Company develops and manufactures affordable and innovative medicines for healthier lives. Company is also building a strong portfolio in lifestyle and chronic segment especially in women healthcare and dermatology to complement our strong presence in acute segment.

The Company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, ant-diabetic, anti-malaria among others. Company has a strong presence in domestic market with good strength of own field force and also exports to more than 60 countries. Company has filed 25 plus patent applications and is awarded with seven patents.

Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, WHO-GMP and ISO-9001: 2015. With the EU certification, company will expand its business network to 90 plus countries. Company currently exports to 60 plus countries including East & West Africa, Central & Latin America and Southeast Asia and has got many product registrations in these countries and is also awarded with number of global tenders.
About Lincoln Pharmaceuticals Limited: https://www.lincolnpharma.com/

Providing Affordable and Innovative medicines for healthier lives.

Lincoln Pharmaceuticals Limited is one of the leading healthcare companies in Gujarat, India. Established in the year 1979, the company develops and manufactures affordable and innovative medicines for healthier lives. The company has developed 300 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. The company have its strong presence in Domestic market with good strength of own field force and also exports to more than 60 Countries.

Company has developed many new drug delivery dosage forms over years and has a track record of launching many first-of-its-kind innovative products. Company works with a vision for nurturing innovations and bringing them to Indian patients at an affordable cost to create "Healthcare for All".

Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with international quality and compliance norms and certified by WHO-GMP and ISO-9001: 2015. Recently company has also received European Union (EU) GMP certification for its manufacturing facility which will allow it to market its products in all the 27 member countries of EU and also give access to European Economic Area (EEA) countries. Company is engaged in manufacturing of pharma formulations like Tablets, Capsules, Injectables, Syrups, Ointments, etc.

Company's key strength is embedded in its cutting-edge research and development capabilities. The company has a strong R&D team including 30 plus scientists. It has filed 25 plus patent applications and is awarded seven patents. R&D centre of the company is recognised by the Department of Scientific and Technology, Government of India and furnished with state-of-the-art devices and equipment for internal physical, chemical and microbiological analysis of all products.

Going green, company has also set up a new Solar Plant of 1 MW at factory's rooftop with a capacity of producing 15 Lakh Power Unit Per annum in addition to two windmills. This way we are producing renewable energy to our consumption nearly 65% resulting significant saving in the electricity cost and helped the company to become a self-sustainable and environment-friendly organization. Company's long term bank facilities are revised from A-/stable to A+/positive and short term bank facilities A2+by ICRA.

Safe Harbor Statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.